drugset / Trial / NCT00315640

Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation

NCT00315640

Phase 2 Completed 70 enrolled Alcon Research
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of anecortave acetate depot when administered for the treatment of elevated IOP following treatment with steroids.

Timeline

Start
2005-12
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Anecortave Acetate Small molecule 3 mg Other
Subject Anecortave Acetate Small molecule 15 mg Other
Subject Anecortave Acetate Small molecule 30 mg Other

Indications